| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Cipla gained global recognition in 2001 when it offered to export anti-AIDS
drug for less than US$1 a day. This report provides an insight into the
company, reviewing its current business structure and activities.
Cipla - Chemical, Industrial & Pharmaceutical Laboratories - was founded in
Bombay, in 1935 by Dr Khwaja Abdul Hamied, a German-trained chemist. The
company's first products were released in 1937. In 1941, as the Second World
War cut off drug supplies to the country, Cipla began producing its own fine
chemicals. In 1952, the company set up its first research division, and in
1960, Cipla's second plant, at Vikhroli in Bombay, commenced operations. The
company started an Agricultural Research Division at Bangalore in 1972, for
the scientific cultivation of medicinal plants, and in 1982, Cipla's fourth
factory commenced operations at Patalganga, Maharashtra. The US FDA first
approved Cipla's bulk drug facilities in 1985, and in 1994, the company's
fifth plant began commercial operations at Kurkumbh, Maharashtra. Cipla's most
recent plant is at Baddi, Himachal Pradesh, and began operations in 2005.
Additionally, Cipla has a joint venture in South Africa, Cipla Medpro, created
with South African generics manufacturer, Medpro Pharmaceutica. Cipla Medpro
is headquartered in Cape Town, and has regional offices in Johannesburg,
Durban, Port Elizabeth, East London and Bloemfontein. The company initiated
the first ever therapeutic equivalence trial in South Africa, comparing one of
its inhaled steroids to the equivalent innovator product, at the Stellenbosch
Medical School. However, Cipla entered an agreement to sell Cipla Medpro to
Enaleni Pharmaceuticals in late 2005. More on this can be found in the Major
Developments section.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS
- FINANCIAL RESULTS
- Latest Yearly Results
- Full Year Results
- Segment Data
- Segment Results
- Geographic Segment Data
- Net Revenues by Region*
- Latest Quarterly Results, third quarter ended 31st December, 2005
(FY2006)
- MAJOR DEVELOPMENTS
- HIV/AIDS
- Clinton Foundation
- Compulsory licensing in Malaysia
- South African antiretroviral tender
- Mergers, acquisitions and agreements
- Akorn
- Cipla Medpro to be sold to Enaleni
- Pentech Pharmaceuticals
- Avestha Gengraine Technologies
- Morton Grove Pharmaceuticals
- Watson Pharmaceuticals
- Stada, Hexal and Fujisawa
- Litigation
- CONTACT DETAILS
|
